Why Novo Nordisk Stock Was Melting on Monday
Key Points
The Wegovy and Ozempic maker was hit with an analyst recommendation downgrade.
A onetime bull now feels the stock is only a hold.
- 10 stocks we like better than Novo Nordisk ›
Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic developer would want. An analyst's downgrade was the catalyst for some shareholders to exit the stock, and as a result, its price was down by more than 2% in mid-session trading.
A Novo Nordisk bull no more
Well before market open, Argus's John Eade changed his Novo Nordisk recommendation to hold from his previous buy. His price target on the stock is now $56 per share.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
According to reports, Eade pointed out in his update that the Denmark-based pharmaceutical company has suffered declines in market share for both of its star drugs. That trend might very well continue, as it will soon have to cope with the introduction of generic products that will rival those treatments.
The analyst is also bearish on Novo Nordisk's progress in the laboratory. He wrote that the company's recent, high-profile clinical trials haven't been impressive. He specifically mentioned a pair of trials testing semaglutide, the active ingredient in Wegovy and Ozempic, as a treatment for Alzheimer's disease. The molecule, alas, did not slow the progression of the disease as hoped.
The perils of popularity
Success begets competition, and Novo Nordisk is fighting a war on several fronts. In addition to those generics makers, it has a very deep-pocketed competitor in this country, the pharmaceutical giant Eli Lilly, with its instantly popular Zepbound obesity drug.
Novo Nordisk management has demonstrated some resilience in this fight, and I believe weight-loss drugs as a category will continue to swell in popularity. That competition isn't going to get any easier, however, so caution is warranted with this stock these days.
Should you invest $1,000 in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $540,587!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,118,210!*
Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 195% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of December 8, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Recommended Articles
